Initial Therapeutics

aid: initial-therapeutics
name: Initial Therapeutics
description: 'Initial Therapeutics, Inc. is a preclinical-stage biotechnology company in South San Francisco, California,
  discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in its
  earliest stages. Its proprietary STOPS platform — Selective Termination of Protein Synthesis — intercepts the translation
  of a target protein inside the exit tunnel of the ribosome, recognizing the nascent primary linear sequence rather than
  a fully folded three-dimensional structure, an approach the company positions as starkly differentiated from targeted protein
  degradation and from interventions that can only act on proteins after they are fully formed. The company launched publicly
  on May 1, 2023 with a $75 million Series A from Apple Tree Partners, was co-founded with academic scientists Jamie H. D.
  Cate (UC Berkeley), Brian Paegel (UC Irvine) and Kevan Shokat (UCSF/UC Berkeley), and builds on ribosome biochemistry, proteomics,
  medicinal chemistry, DNA-encoded library technology and chemical genetics, with early programs aimed at oncology targets
  long considered undruggable. Initial Therapeutics is a therapeutics discovery company, not a software vendor: it publishes
  a small marketing website and no public API, SDK, developer portal or machine-readable contract of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/initial-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
specificationVersion: '0.20'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Biotechnology
- Therapeutics
- Drug Discovery
- Small Molecule
- Oncology
- Life Sciences
- Preclinical
tags_raw:
- Company
- Biotechnology
- Therapeutics
- Drug Discovery
- Small Molecules
- Oncology
- Life Sciences
- Preclinical
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/initial-therapeutics-domain-security.yml
- type: Website
  url: https://initialtx.com/
- type: TermsOfService
  url: https://initialtx.com/terms-of-use.html
- type: PrivacyPolicy
  url: https://initialtx.com/privacy-policy.html
- type: LLMsTxt
  url: llms/initial-therapeutics-llms.txt
x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Initial Therapeutics is a preclinical small-molecule drug-discovery company whose entire web presence is a five-page
    marketing site on shared SiteGround hosting, where every contract path (/openapi.json, /graphql, /llms.txt, /.well-known/*)
    returns the identical site-wide HTTP 202 robot-challenge body that a deliberately bogus path returns, and api./docs./developer.initialtx.com
    are wildcard DNS onto SiteGround's default vhost (403, certificate CN=gvam1148.siteground.biz) — there is no API here
    to gate, to read, or to hide.
  evidence:
  - url: https://initialtx.com/openapi.json
    status: 202
  - url: https://initialtx.com/.well-known/agent-card.json
    status: 202
  - url: https://api.initialtx.com/openapi.json
    status: 403
  - url: https://pypi.org/pypi/initialtx/json
    status: 404
  checked: '2026-08-23'